In 2023, the U.S. FDA approved 55 new drugs, 17 of which were biopharmaceuticals. Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, contributed to four, which equals nearly 25% of these biopharmaceuticals.   Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, commented: “Guiding a promising therapy from its initial clinical trials to commercialization is a demanding endeavor that spans numerous years ...